Recent Press Releases

Stellar Biotechnologies Announces Exclusive Option to License Clostridium Difficile Technology

Stellar Biotechnologies Announces Exclusive Option to License Clostridium Difficile Technology April 10, 2012 Stellar Executes Agreement with University of Guelph for Vaccine Research Port Hueneme,...

Biovest to Seek Marketing Approval for BiovaxID® Personalized Lymphoma Cancer Vaccine in Canada

Biovest to Seek Marketing Approval for BiovaxID® Personalized Lymphoma Cancer Vaccine in Canada 04/10/12 Biovest International, Inc. (OTCQB: BVTI), a majority-owned subsidiary of Accentia...

Follow-up studies offer clues to how RV144 vaccine may have protected against HIV

Follow-up studies offer clues to how RV144 vaccine may have protected against HIV April 5, 2012 (SILVER SPRING, Md.) -- Researchers have discovered important clues about the immune responses that may...

Possible clues found to why HIV vaccine showed modest protection

Possible clues found to why HIV vaccine showed modest protection Analysis by NIH-supported scientists may help identify requirements for HIV vaccine Wednesday, April 4, 2012 Insights into how the...

Manipulating the immune system to develop 'next-gen' vaccines

Manipulating the immune system to develop 'next-gen' vaccines 06/04/12 Researchers (from left) Dr Jian-Guo Zhang, Dr Mireille Lahoud, Dr Peter Czabotar and Professor Ken Shortman have discovered how...

GAVI Alliance secures lower price for rotavirus vaccine

GAVI Alliance secures lower price for rotavirus vaccine New deal secured for rotavirus vaccines reduces price by two-thirds, signaling potential market impact of US$ 650 million Geneva, 10 April 2012...

Vaxil BioTherapeutics announces positive interim results from its Phase I/II therapeutic cancer vaccine trial in Multiple Myeloma patients

Vaxil BioTherapeutics announces positive interim results from its Phase I/II therapeutic cancer vaccine trial in Multiple Myeloma patients The interim results were reported in regulatory filings made...

Chile Stops Use of Mercury in Vaccines

Chile Stops Use of Mercury in Vaccines WASHINGTON, April 3, 2012 /PRNewswire via COMTEX/ -- Decision Comes as WHO Meets to Discuss Global Treaty on Mercury Use Chile has become the first developing...

Inovio Pharmaceuticals Receives Defense Department Funding for Bioterrorism-Related Synthetic Vaccine Program

Inovio Pharmaceuticals Receives Defense Department Funding for Bioterrorism-Related Synthetic Vaccine Program Second DOD grant extends development and testing of novel surface electroporation...

Phase III Research Represents Potential Shift in Standard of Care for Non-muscle-invasive Bladder Cancer

Phase III Research Represents Potential Shift in Standard of Care for Non-muscle-invasive Bladder Cancer April 2, 2012 - Connaught strain of bacillus Calmette-Guérin proved superior. -...

Efficacy and Safety Data for ZOSTAVAX® (Zoster Vaccine Live), Merck's Shingles Vaccine, in Adults Ages 50 to 59 Published in Clinical Infectious Diseases

Efficacy and Safety Data for ZOSTAVAX® (Zoster Vaccine Live), Merck's Shingles Vaccine, in Adults Ages 50 to 59 Published in Clinical Infectious Diseases WHITEHOUSE STATION, N.J., April 2,...

Astellas and Vical Advance Toward Phase 3 Trial of TransVax(TM) CMV Vaccine Triggering $10 Million Milestone Payment to Vical

Astellas and Vical Advance Toward Phase 3 Trial of TransVax(TM) CMV Vaccine Triggering $10 Million Milestone Payment to Vical SAN DIEGO, Apr 2, 2012 (GlobeNewswire via COMTEX) -- Vical Incorporated...

Peptide Vaccine Stimulates Immune Response in Patients With Breast Cancer

Peptide Vaccine Stimulates Immune Response in Patients With Breast Cancer April 2, 2012 - Patients with breast cancer responded well to vaccine for recurrence prevention. - T regulatory cells...

Peptide Vaccine Shows Evidence of Immunological, Clinical Activity in Children With Gliomas

Peptide Vaccine Shows Evidence of Immunological, Clinical Activity in Children With Gliomas April 2, 2012 - Eighteen of 22 children had regression, stable disease for more than three months....

Measles-Containing Vaccines not Associated with Increased Risk of Febrile Seizures in Children Ages 4–6

Measles-Containing Vaccines not Associated with Increased Risk of Febrile Seizures in Children Ages 4–6 OAKLAND, Calif. — Vaccines for measles were not associated with an increased risk...

Immunovaccine Presents Findings of Cancer Vaccine Studies at AACR Meeting

Immunovaccine Presents Findings of Cancer Vaccine Studies at AACR Meeting Halifax, CANADA, April 3, 2012 – Immunovaccine Inc. (TSX-V: IMV) announced new findings today at the 2012 American...

Vaccine Yielded Encouraging Long-term Survival Rates in Certain Patients With NSCLC

Vaccine Yielded Encouraging Long-term Survival Rates in Certain Patients With NSCLC April 4, 2012 -Patients with nonprogressive disease had improved survival rates. -Five-year survival rate...

Immune therapies: the next frontier in battle against atherosclerosis

Immune therapies: the next frontier in battle against atherosclerosis Frontiers in CardioVascular Biology 2012 London, 30 March 2012: New strategies injecting cardiovascular disease (CVD) patients...

Inviragen Hand, Foot and Mouth Disease Vaccine Generates Immune Responses in 100% of Study Participants


Inviragen Hand, Foot and Mouth Disease Vaccine Generates Immune Responses in 100% of Study Participants